GT Biopharma
Open
$0.31
Prev. Close
$0.31
High
$0.31
Low
$0.31
Market Snapshot
$2.89M
-0.1
-7.00
1
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
emptyResult
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
Recently from Cashu
GT Biopharma Advances Immuno-Oncology with IND Application for GTB-5550 Targeting Solid Tumors
GT Biopharma Advances Immuno-Oncology with New Drug Application for GTB-5550 GT Biopharma, Inc. stands at the forefront of a transformative era in precision medicine, particularly in the realm of immu…
GT Biopharma's Innovative NK Cell Engagers Transforming Precision Oncology Landscape
GT Biopharma's Innovative Approach to Precision Oncology GT Biopharma, Inc. (NASDAQ: GTBP), a clinical-stage immuno-oncology company, stands at the forefront of a transformative shift in the precision…
GT Biopharma Innovates Immuno-Oncology with Advanced Therapy GTB-3650 for Blood Cancers
GT Biopharma Advances Immuno-Oncology with Innovative Therapy Development GT Biopharma, Inc. is leading the charge in the oncology sector's transition to platform-based precision therapies, a movement…
GT Biopharma Advances Immuno-Oncology with TriKE Platform in Groundbreaking Trials
GT Biopharma Advances Immuno-Oncology Trials with Innovative TriKE Platform GT Biopharma, Inc. is making significant strides in the immuno-oncology landscape with its ongoing clinical trials for GTB-3…